Propylene glycol accumulation in critically ill patients receiving continuous intravenous lorazepam infusions. - Wikidata - awgldk - TriplyDB

Propylene glycol accumulation in critically ill patients receiving continuous intravenous lorazepam infusions.

Propylene glycol accumulation in critically ill patients receiving continuous intravenous lorazepam infusions.

http://www.wikidata.org/entity/Q43240250

about

Heavy use versus less heavy use of sedatives among non-medical sedative users: Characteristics and correlates Propylene glycol toxicity in children.Sedation, analgesia, and delirium in the critically ill patient.Sedation and analgesia in the mechanically ventilated patient.Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.Emergency neurological life support: airway, ventilation, and sedation.Emergency Neurological Life Support: Airway, Ventilation, and Sedation.Development and Evaluation of a Guideline for Monitoring Propylene Glycol Toxicity in Pediatric Intensive Care Unit Patients Receiving Continuous Infusion Lorazepam.Serum osmolal gap in clinical practice: usefulness and limitations.Considerations for analgosedation and antithrombotic management during extracorporeal life support.A Review of Agents for Palliative Sedation/Continuous Deep Sedation: Pharmacology and Practical Applications.A Symptom-Triggered Benzodiazepine Protocol Utilizing SAS and CIWA-Ar Scoring for the Treatment of Alcohol Withdrawal Syndrome in the Critically Ill.Effect of Extracorporeal Membrane Oxygenation Use on Sedative Requirements in Patients with Severe Acute Respiratory Distress Syndrome.Emergency Neurological Life Support: Airway, Ventilation, and Sedation.Drug-induced hyperlactatemia.

P2860

Q34311279-595DBAF4-2E81-4ADA-ABED-B054A17B1B61 Q35124117-B654D769-AA93-4DEF-B987-D80A7677808D Q37867312-E744463C-7050-48B2-A9EC-FB8B760950BA Q37948029-9285286F-E035-4581-8079-D1C7A8524BEE Q38040844-91AF1885-E09C-4D71-9407-DE7B3EDE8ABC Q38042830-F4673A25-C355-4A9D-A070-389EDB60E625 Q38599740-535DF4AC-483F-4FD5-864A-D47EE26463BC Q38608791-B25548A7-061C-4F99-B397-B1ED60410356 Q38901212-7E82CF71-4E27-48F0-9D6F-C3225C60E258 Q39169651-5E969935-3D52-4060-9BA1-DD041B7941DE Q39175922-CA08450D-8E5C-47E5-89D7-43FB89018D30 Q39297857-92026434-985C-46E1-86B2-E04184A3284F Q39808379-CAB02CB7-F889-460A-9D2F-B6F369113A1B Q48111715-2C7D14BB-AB71-40AA-8219-59CE99FB6949 Q53797180-BF2033C7-DE8A-4D6D-88C4-508AAED45420

P2860

Propylene glycol accumulation in critically ill patients receiving continuous intravenous lorazepam infusions.

http://www.wikidata.org/entity/Q43240250

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Propylene glycol accumulation ...... travenous lorazepam infusions.

@en

Propylene glycol accumulation ...... travenous lorazepam infusions.

@nl

type

label

Propylene glycol accumulation ...... travenous lorazepam infusions.

@en

Propylene glycol accumulation ...... travenous lorazepam infusions.

@nl

prefLabel

Propylene glycol accumulation ...... travenous lorazepam infusions.

@en

Propylene glycol accumulation ...... travenous lorazepam infusions.

@nl

P1433

Q43240250-4F6D1E54-E0DD-4E32-B457-D6853724BEDA

P1476

Q43240250-6D1D3E35-F5E7-46A0-AC4B-2183D8B8027A

P2093

Q43240250-08F97262-4431-4821-A939-FFB411B57145

Q43240250-3D32888A-0927-4C87-BF73-3D7CAEE785CD

Q43240250-932F386F-3AE7-4033-BC20-1C610E679DC9

P2860

Q43240250-1E5CE6BE-13EA-42C0-A38A-289A0F049556

Q43240250-613D89CC-95D0-43A5-B554-FEE64435B6D8

Q43240250-7F394E0E-8A24-47DB-9859-DE594F99E52C

Q43240250-B9D57F18-3218-4F42-9F32-DAD149669BFD

Q43240250-F088AAB9-2F98-48B6-B8B5-3F2D01987E4E

Q43240250-F1B56A48-4C90-4F9F-8B28-6D0DEACC4108

Q43240250-F689292B-2A64-4CB9-B04B-6EF572BAA47A

Q43240250-FC37D7B5-764E-4BA5-96EE-D168D82768DD

P304

Q43240250-0C8DB12D-91AA-4FDF-B28C-AE2A01B65663

P31

Q43240250-6AEE26B6-7537-48B8-940A-BC190BB949AC

P356

Q43240250-C2189812-448F-4274-8898-D0FBAF575BE3

P407

Q43240250-C6B13246-51F3-4F5B-8B34-BA0D25EFCC62

P433

Q43240250-E6D9B538-FB65-4AD9-9848-2836E1A1BF2D

P478

Q43240250-5CBDBF1A-8EE7-45C4-9C7C-E890FD0C134F

P50

Q43240250-5D19B223-551E-4740-9380-DA5D85C53A08

P577

Q43240250-091F49E3-E0FA-4530-AE28-8BF1E80A55F0

P698

Q43240250-D9E71FE5-BCB4-4CA1-AACE-95209C95B988

P356

P1433

Annals of Pharmacotherapy

P1476

Propylene glycol accumulation ...... travenous lorazepam infusions.

@en

P2093

Douglas N Fish

http://www.w3.org/2001/XMLSchema#string

Erica L Horinek

http://www.w3.org/2001/XMLSchema#string

Robert MacLaren

http://www.w3.org/2001/XMLSchema#string

P2860

APACHE II: a severity of disease classification system

Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult.

Propylene glycol-associated renal toxicity from lorazepam infusion.

Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study.

Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation.

Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults.

Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity.

A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients.

P304

1964-1971

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1M313

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19920159

http://www.w3.org/2001/XMLSchema#string